Melanoma

Liposomal trafficking leads antisense molecules directly to destination

Published in Gene Therapy Weekly, September 26th, 2002

by Sonia Nichols, senior medical writer - A research team at the University of British Columbia in Canada has developed a liposomal delivery system that increases the ability of antisense oligonucleotides (ODNs) to get to their destination.

Although ODNs are considered valuable molecules for use in gene therapies, their properties often make them less than optimal barrier crossers. Enlisting a more effective carrier vehicle would be one way to overcome that problem, scientists say.

"This carrier should assist antisense ODNs to penetrate the cell membrane and, once inside the cell, release the ODNs and make them available for target binding," Qiang...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry